Eighteen months after the onset of his deterioration, he experienced an exacerbation of his ABPA, as shown by a second sharp rise in his serological indicators ( Figure 2 ) in association with new confluent radiographic shadowing. Oral corticosteroids were recommenced at the higher dose of 2 mg/kg/day with a better response. However, he remains steroid-dependent, and suffers from glucose intolerance, obesity and growth delay. 
CASE HISTORY
KW was diagnosed with cystic fibrosis aged one. Sweat sodium was 82 mEq/ml, and genetic analysis has since confirmed homozygosity for delta F508. Allergic bronchopulmonary aspergillosis (ABPA) developed aged eight, with a fall in lung function and typical radiological and serological changes. He responded well to treatment with conventional dose oral prednisolone (I mg/kg/day).
At the age of 12, having remained extremely well, he developed acute wheeze, breathlessness, and markedly decreased exercise tolerance. Lung function fell dramatically ( Figure 1 ). There was no radiological evidence of ABPA, acute infection or bronchiectasis, but both chest X-ray and computerized tomography (CT) showed patchy air-trapping indicating small airways obstruction. There was no serological evidence of a recrudesence of ABPA, and viral and auto-immune screens were negative. There was only a transient response to intravenous antibiotics, and he subsequently failed to respond to oral prednisolone I mg/ kg/ day, nebulized and intravenous salbutamol, intravenous aminophylline, and further antibiotics. He has since failed to respond to a 6 month course of low-dose methotrexate
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This child presents difficult management problems. The aetiology of his acute deterioration remains uncertain. The criteria for ABPA were not initially fulfilled!. We considered that resistant mucus plugging was unlikely because of the sudden onset in a well child and the lack of response to nebulized DNase. Likewise, we felt that severe bronchospasm was unlikely because of the lack of response to bronchodilators. A serological screen for both viral and auto-immune disease was negative, so this episode represented small airway inflammation of an unknown aetiology, which was resistant not only to corticosteroids but alsoto methotrexate and cyclosporin A-both of which are known to be potent anti-inflammatory agents and have been used with some success in steroid-dependent asthma 2 ,3. The main management problem remains, however, one of further treatment. Intravenous immunoglobulin has been used with some success in both infective exacerbations of CF(4-) and severe childhood asthma>, and has the benefit of a high safety profile. Weare also considering the use of the anti-fungal agent, itraconazole, as adjunctive treatment for his relapsed ABPA6. Should these approaches fail, an alternative anti-inflammatory agent, such as azathioprine, may be considered. The possible future requirement for lung transplantation has been discussed, but at present the family are opposed to this, and, currently, acceptance onte a transplantation waiting-list would depend on our ability to maintain symptomatic control without high-dose steroids. CONCLU~ON \ Airway obstruction in CF is usually related to severe bronchiectasis. This is not the case with this child, who presents difficult diagnostic and management problems. Response to various forms of treatment has been disappointing, control only being achieved with unacceptably high doses of oral steroids, and alternative therapies are now being considered.
ADDENDUM
Following the submission of this case report, the decision was made to attempt steroid reduction with the use of high dose intravenous immunoglobulin (IVIG). This was administered on a monthly basis, with an initial dose of 0.4 g/kg for 4days followed by monthly doses of 1g/kg. By the third dose, prednisolone dose had been reduced by half, and by the end of a 6 month course, was withdrawn completely, with maintainance of lung function. Four months after his last dose of IVIG, and still off oral steroids, he remains well, with an excellent exercise tolerance,· and lung function values greatly improved at FVC 105%, FEV! 63% and FEF 25-75% 29% of predicted.
